Key facts
- This page summarizes Scott Hutton's Form 4 filing for BIODESIX INC (BDSX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Feb 2022, 18:08.
Scott Hutton - 08 Feb 2022 Form 4 Insider Report for BIODESIX INC (BDSX)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- BDSX
- Reported as of
- 08 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Feb 2022, 18:08:56 UTC
- Prior SEC filing
- 18 Nov 2021
- Next SEC filing
- 11 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robin H. Cowie as Attorney-in-Fact for Scott Hutton
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott Hutton filed Form 4 for BIODESIX INC (BDSX) on 10 Feb 2022.
Change
- Previous filing in this sequence was filed on 18 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BDSX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +195,392
- Change %
- Price
- $0.000000
- Shares after
- 195,392
- Date
- 08 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 195,392
- Exercise price
- Footnotes
- F1, F2
BDSX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +195,393
- Change %
- Price
- $0.000000
- Shares after
- 195,393
- Date
- 08 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 195,393
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
Footnote F2
These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.
Footnote F3
These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.